Clark Zhang Ph.D.

Clark Zhang is a senior associate providing strategic intellectual property counsel to companies involved in developing cutting edge innovations in both the life sciences and high-tech industries.

Clark closely partners with companies across all stages of development including early stage, venture-backed, and late stage companies in developing valuable patent portfolios, evaluating competitive landscapes, conducting IP diligence, and raising capital. As every client’s business needs are different, Clark seeks to thoroughly understand the needs of each client to provide tailored, solution-oriented advice to address those needs.

Clark’s technical expertise involves machine learning, bioinformatics, digital health, computational biology, sequencing technologies, medical devices, antibody therapies, nucleic acid therapies, and genetic editing.

IP Portfolio Strategy and Development

• Insitro, inc., a company seeking to decode human biology with machine learning for discovering new therapies
• Flagship Pioneering, a bioplatform innovation and venture capital company on development of intellectual property across a variety of technical disciplines
• Harbinger Health, Inc., a company combining advances in artificial intelligence and proprietary insights into biology for early detection of cancer
• Gritstone bio, a biotechnology company developing personalized immunotherapies using proprietary machine learning technologies
• Mission Bio, Inc., a company developing single cell analysis platforms at single-base resolution, resulting in successful conclusion of Series C and Series D financings (totaling over $130 million)
• QurAlis, Inc., a biotech company developing nucleic acid therapies for neurological disorders, on intellectual property matters, resulting in successful out-licensing of lead therapeutic program
• New York Stem Cell Foundation, a nonprofit supporting stem cell research and clinical trials for various diseases.
• Octave Bioscience, a precision-medicine company offering a data-driven platform to measure and monitor multiple sclerosis progression and response
• Ultragenyx Pharmaceutical, a biopharmaceutical company developing various therapies (including nucleic acid therapies) for rare diseases
• Interius Biotherapeutics, Inc., a biotechnology company developing in vivo CAR therapies

Prior to joining Goodwin, Dr. Zhang was a patent agent at Fenwick & West LLP representing various clients in the high-tech industries. Prior to that, Clark pursued his doctoral thesis in the Center for Nanomedicine at Johns Hopkins University, where he focused on engineering drug and gene nanoparticles for delivery and treatment of neurological diseases.

• Co-Author, “Ahead of the Curve,” Intellectual Property Magazine, (pages 22-24), June 2021
• “The Evolving Standard for Patent Claim Definiteness,” Daily Journal, February 2018.
• “NAFTA Renegotiation of Intellectual Property Provisions,” Daily Journal, April 2018.
• “Convection Enhanced Delivery of Cisplatin-Loaded Brain Penetrating Nanoparticles Cures Malignant Glioma in Rats,” Journal of Controlled Release, October 2017, 263, 112-119.
• “Strategies to Achieve Maximal Nanotherapeutic Distribution in the Brain,” Journal of Controlled Release, December 2017, 267, 232-239.